Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
173
resultados
Última actualización
02/11/2026 [10:52:00]
Resultados 25 a 50 de 173
Resumen de: US20260327703A1
0000 The present invention relates to microRNAs for use in diagnostic methods for diagnosing and/or for distinguishing by diagnosis Alzheimer's disease (AD), Frontotemporal Dementia (FTD), and possibly other tauopathies, and/or for measuring therapeutic effect of a treatment of FTD or AD.
Resumen de: US20260325476A1
0000 Disclosed are methods for inhibiting the progression of neurodegenerative disease. The methods include administering to a patient suffering from such a disease a composition comprising either deuterated linoleic acid or an ester thereof.
Resumen de: US20260327296A1
0000 The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encelopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: WO2026220933A1
Provided is a pharmaceutical composition that has fewer side effects and that makes it possible to obtain an effect of preventing or treating Parkinson's disease A pharmaceutical composition for preventing or treating Parkinson's disease according to an embodiment of the present invention contains a nucleic acid that inhibits the expression of Rap1GAP.
Resumen de: WO2025128873A1
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
Resumen de: WO2025128848A1
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
Resumen de: WO2025128781A1
Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.
Resumen de: CN122422322A
Novel compounds of formula (I), and pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and are useful in the treatment, prevention, management, amelioration, control and inhibition of diseases mediated by NLRP3. The compounds of the invention are useful for treating, preventing or managing diseases, disorders and conditions mediated by NLRP3, such as, but not limited to, NLRP3. Obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's disease, Parkinson's disease, Lewy body dementia (DLB) and traumatic brain injury. (I).
Resumen de: WO2025125135A1
The invention provides new heterocyclic compounds having the general formula (I) wherein X, Y, A, B, C, and R1 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as soluble epoxide hydrolase inhibitors.
Resumen de: AU2025255577A1
The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.
Resumen de: AU2026238094A1
METHODS AND COMPOSITIONS FOR MODULATION OF TAU The present disclosure is in the field of diagnostics and therapeutics for Alzheimer’s Disease. ep e p
Resumen de: AU2025233448A1
The present disclosure provides methods of treating Alzheimer's disease and other disorders using (4R,5R)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one (Compound 1).
Resumen de: WO2026215661A1
The present disclosure relates to the use of a bisphosphonate, specifically tiludronate, etidronate, clodronate, pamidronate, zoledronate, and combinations thereof, for the treatment of neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, among others. Additionally, the disclosure encompasses a method for treating neurodegenerative disorders by administering an effective amount of a bisphosphonate to a subject in need thereof.
Resumen de: WO2026215248A1
The present invention concerns the treatment of neurodegenerative disorders and provides for novel treatments for such disorders, Alzheimer disease, Parkinson Disease and Amyotrophic Lateral Sclerosis in particular. It is also directed to novel therapeutic combinations useful for treating such disorders.
Resumen de: WO2026217520A1
The present disclosure provides methods and compositions for treating Amyotrophic Lateral Sclerosis (ALS) in a subject in need thereof. In certain embodiments, the method comprises administering to the subject an effective amount of a composition comprising a recombinant adeno-associated virus (AAV) vector comprising a nucleic acid encoding a trophic factor operably linked to a muscle-specific promoter. In certain embodiments, the trophic factor is Brain-Derived Neurotrophic Factor (BDNF). In certain other embodiments, the trophic factor is Growth Arrest-Specific 6 (GAS6).
Resumen de: WO2026217660A1
Compositions comprising a pharmaceutically effective amount of diamine oxidase (DAO) or a homolog thereof, for the generation of active polyamine metabolites in a subject in need thereof. The compositions may further optionally include one or more polyamines and/or one or more polyphenols. Senolytic compositions comprising DAO and tetramethoxyluteolin (TML) for selectively targeting and eliminating senescent cells are also provided. In certain embodiments, the disclosed compositions and methods of using the compositions are effective for the treatment or prevention of, among other conditions and disorders, inflammation and inflammation-related disorders, allergies and allergic reactions, mast cell disorders including MCAS, histamine intolerance, and various age-related disorders including Alzheimer's disease, Parkinson's disease, and systemic sclerosis. The Applicant has recognized that the beneficial effects of polyamine therapy are derived from polyamine metabolites generated through DAO-mediated enzymatic conversion, and that unmetabolized polyamines can activate mast cells via MRGPRX2, causing or exacerbating allergic and inflammatory states.
Resumen de: WO2026217770A1
The disclosure provides compounds, in part, compounds of Formula I and their use in treating medical diseases or disorders, such as neurodegenerative diseases, e.g., Parkinson's disease. Pharmaceutical compositions and methods of making compounds of the disclosure are provided. The compounds are contemplated to be modulators, e.g., inhibitors, of cyclic ADP ribose hydrolase (CD38).
Resumen de: WO2026217497A1
The present disclosure relates to compounds that are capable of inhibiting PRMT8 and/or upregulating SirTl. The disclosure further relates to methods of treating neurodegenerative diseases and disorders (e.g., Alzheimer's disease) using such compounds.
Resumen de: WO2026215819A1
The present invention relates to the field of organic chemistry and drug design. Here, the present invention provides a novel substituted quinazolinone compound of formula I and a robust and reproducible method of preparation of the heterocyclic compound of formula I for the management of Alzheimer's disease. The method of synthesis comprises of formation of a heterocyclic intermediate of formula II through the preparation of a benzoic acid intermediate and metal free cyclization of the benzoic acid intermediate and further subjecting the heterocyclic intermediate of formula II to C–N bonding with substituted aromatic amines by Buckwald Hartwig reaction to yield the heterocyclic compound of formula I. Moreover, the present invention provides pure heterocyclic compound with higher yields with milder reaction conditions, environment friendly and cost-effective reactants and reagents for management of Alzheimer's disease.
Resumen de: WO2026217569A1
Methods and compositions for treating Alzheimer's disease and related neurodegenerative conditions using intranasal nose-to-brain delivery of ST266, an amnion-derived cell secretome are described. ST266 is a multi-component, acellular biologic composition produced from amnion-derived multipotent progenitor (AMP) cells under cGMP conditions and comprising a plurality of anti-inflammatory, neuroprotective, anti-apoptotic, and regenerative cytokines and growth factors. When administered intranasally, ST266 bypasses the blood-brain barrier and simultaneously targets multiple pathological mechanisms underlying Alzheimer's disease, including neuroinflammation, insulin dysregulation, oxidative stress, neuronal damage, and synaptic dysfunction. The invention encompasses pharmaceutical compositions formulated for intranasal nose-to-brain delivery, methods of treating Alzheimer's disease by administering such compositions, and methods of reducing neuroinflammation and improving insulin regulation in the central nervous system. The non-invasive nature of intranasal delivery offers significant advantages in patient compliance and minimization of systemic side effects.
Resumen de: US20260317296A1
0000 Provided are heterocyclic compounds of Formula I or Formula II or their pharmaceutically pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers for imaging tau aggregates. Compounds of Formula I or Formula II may be used for the detection of tau aggregates in the diagnosis or monitoring of the progression of a disease or disorder such as Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy.
Resumen de: US20260317384A1
0000 The disclosure provides humanin mimetics that increase neuronal p-AKT and enhance p-gp130 as a new therapeutic class for chronic diseases such as Alzheimer's disease.
Resumen de: US20260315626A1
0000 The present relates to polynucleotide constructs encoding an ApoE3 related protein optionally containing one or more intron. Potential uses of the different constructs include gene therapy targeting one or more disease or disorder, for example, diseases or disorders related to cholesterol levels, atherosclerosis, coronary heart disease, dementia, cerebral amyloid angiopathy, or Alzheimer's disease.
Nº publicación: US20260315423A1 15/10/2026
Solicitante:
AMNEAL PHARMACEUTICALS LLC [US]
Amneal Pharmaceuticals, LLC
Resumen de: US20260315423A1
The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
BOPI
Sede Electrónica
